November 2026 - Dihydroorotate Dehydrogenase Inhibitors drug patent information, international generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-002	Sep 12, 2012	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 28, 2026

DHODH inhibitors are positioning as oral, targeted therapies in autoimmune and inflammatory disease areas with durable oral efficacy potential. The patent landscape is concentrated in (i) substituted DHODH inhibitor small molecules, (ii) polymorphs/salts and solid forms, (iii) formulation and dosing patents, and (iv) method-of-use claims tied to inflammatory/autoimmune indications. Market dynamics are being set by trial outcomes, payer access, and competitive timing with IL-1/IL-6/JAK and conventional immunosuppressants, while IP risk is driven by how broadly independent claims cover chemical space and by whether later-expiring formulation/polymorph claims narrow design-around freedom.

This report outlines the patent architecture and commercial entry risks across DHODH inhibitor programs, with an emphasis on actionable timing questions: which estates likely anchor exclusivity, when patents expire, and where Paragraph IV-style pathways are plausibly relevant.

Which dihydroorotate dehydrogenase (DHODH) inhibitors are leading the market and what drives their adoption?

DHODH inhibitors target de novo pyrimidine biosynthesis by blocking mitochondrial DHODH, reducing uridine nucleotide pools and suppressing lymphocyte proliferation and inflammatory signaling. Commercial adoption hinges on clinical durability, safety in long-term use, and uptake vs standard-of-care immunomodulators.

What indications are DHODH inhibitors targeting most often?

Across the class, lead programs concentrate on autoimmune and inflammatory disease, typically:

Rheumatoid arthritis and other inflammatory arthritides
Psoriasis/psoriatic disease
Systemic lupus erythematosus (SLE) and related autoimmune syndromes
Multiple sclerosis and neuroinflammatory conditions
Vasculitis and inflammatory bowel disease (program-dependent)

Market share outcomes are strongly coupled to the product’s positioning vs biologics and JAK inhibitors, including:

Oral convenience vs injection/infusion
Infection risk profile vs broad immunosuppression
Lab monitoring burden and tolerability vs kinase inhibitors
Rapid onset vs delayed disease control patterns

What are the market dynamics shaping pricing and uptake?

Safety differentiation: DHODH inhibition is often promoted as pathway-specific rather than cytokine blockade. Payers and clinicians weigh infection risk, lipid changes, hepatic monitoring, and GI tolerability.
Combination strategy: If protocols allow background methotrexate or other stable regimens, uptake accelerates through existing treatment pathways.
Head-to-head trial endpoints: Competitive advantage depends on durability measures (weeks to response, sustained remission rates, flare reduction).
Manufacturing scale and cost: As oral small molecules, supply chains often become differentiators. IP-protected synthetic routes can raise entry costs even if chemical claims are weak.

How strong is the DHODH inhibitor patent estate and what types of patents dominate?

DHODH inhibitor estates often show a layered structure:

Core chemical composition patents

Broad Markush structures and substitution patterns covering DHODH inhibitor analogs.
Independent claims covering compounds defined by chemical features that map to DHODH binding and enzyme inhibition.

Solid-state and polymorph patents

Salt forms, solvates, hydrates, and polymorphs.
Crystallographic descriptors and stability data.
These can extend exclusivity even after earlier composition-of-matter terms.

Formulation and dosing patents

Granulations, tablets/capsules, controlled-release systems, and particle engineering.
Specific dosing regimens (dose titration and titration schedules).
Food-effect and bioavailability optimization.

Method-of-use patents

Indication-specific claims tied to clinical endpoints.
Treatment regimens for defined populations (seropositive, inadequate responder, disease severity stratification).
These claims may be enforceable even if generic compounds exist, depending on infringement theory and claim scope.

Manufacturing process patents

Synthetic steps and intermediate claims.
Process windows, purification methods, and catalyst specifications.
These are most relevant in blocking entry when compound claims are weak but process claims remain.

Which patents protect dihydroorotate dehydrogenase inhibitors (DHODH inhibitors) in the US and EU?

A complete “patent-by-patent” mapping requires each specific DHODH inhibitor product’s identity, brand name, active ingredient, and reference drug listing. Without those inputs, the only accurate statement is that DHODH inhibitor IP is dominated by small-molecule composition and solid-state claims, with method-of-use protection varying by jurisdiction and claim drafting.

Given the class-level constraint, the practical approach for investors and licensors is to build a dossier per candidate program:

Identify the first US filing (priority date) for the lead chemical series.
Extract later filings for salts/polymorphs and formulation.
Identify method-of-use patents linked to the approved label.
Cross-check family members in EP and national filings in key markets (US, EP, UK, DE, FR, IT, ES, CA, JP).

This is the same sequence used in enforcement and freedom-to-operate (FTO) reviews for oral small molecules.

Hurdle for design-around

DHODH inhibitors can have high claim entanglement when:

Markush claims include most “ring” substitutions around the pharmacophore.
Polymorph claims cover the specific solid form selected for commercial supply.
Method-of-use claims are written to cover broad patient groups, not only narrow phenotypes.

When does DHODH inhibitor exclusivity end, and what timelines drive generic or follow-on competition?

For oral small molecules, market exclusivity is typically determined by:

Patent term from earliest non-provisional filing (20-year baseline, subject to adjustments)
Patent term extensions where applicable (US PTA) for time lost during review
Additional regulatory exclusivity (data exclusivity and marketing exclusivity) when relevant to the approval pathway
Patent term offset from formulation/polymorph or method-of-use families that expire later than the core compound family

What “clock” matters most for DHODH inhibitors?

Earliest priority date for the core compound
Whether the approved product has US Patent Term Adjustment (PTA)
Whether late-cycle solid-state/formulation patents extend enforceability
Whether any method-of-use patents align tightly to the label so that generic entry triggers infringement theories

Typical entry scenarios

Scenario A: weak chemical coverage, strong formulation coverage
Generic may launch the API but face injunction risk or supply delay if the same polymorph/salt/formulation is required for bioequivalence.
Scenario B: strong chemical coverage, weak method-of-use
Generic can be blocked until composition patents expire; once they do, follow-on method-of-use patents may slow some labeling but may not prevent off-label use.
Scenario C: broad Markush chemical coverage
Design-around becomes expensive; generic filing may be delayed until a fully non-infringing series is available.

What generic entry risks exist for DHODH inhibitors, including Paragraph IV pathways?

Are Paragraph IV challenges likely for DHODH inhibitor products?

In practice, Paragraph IV filings become most likely when:

At least one US listed patent covers the product but has an earlier expiration date than the perceived investment horizon
The composition claims appear narrow enough to allow a non-infringing generic compound
Or formulation/polymorph patents appear enforceable but susceptible to design-around via alternate solid forms

How settlement agreements typically shape entry

When Paragraph IV litigation is plausible:

Generic manufacturers seek launch-at-risk timing.
Brand manufacturers seek automatic stay management through quick settlement.
Settlement can delay entry while permitting future non-infringing reformulations or narrowed labeling.

What increases litigation density for this class

Solid-state claims with commercial supply lock-in
Method-of-use claims that track label wording
Families that include both composition and intermediate claims that complicate invalidity narratives

What Orange Book status issues apply to DHODH inhibitors and how does it affect launch timing?

For US regulatory strategy, the Orange Book determines whether a generic applicant must address listed patents. For DHODH inhibitors:

Orange Book listings tend to include composition and often formulation-related patents once a specific solid form is commercialized.
If multiple patents are listed for the same NDA, the generic applicant may face multi-front litigation.

What matters operationally in Orange Book review

Patent list count and staggered expiration dates
Whether the “most relevant” patents are chemical, formulation, or method-of-use
Whether any patent is a formulation for a specific dosage form (tablet/capsule) that the generic must replicate for bioequivalence

What formulations are protected for DHODH inhibitors and how can that block design-around?

Solid-state IP is a major entry barrier because:

Bioequivalence can depend on physical form and dissolution behavior.
Alternate polymorphs can change dissolution and raise bioequivalence failure risk.

Common protected formulation elements

Salt selection and conversion control (stability in humidity/light)
Particle size and milling parameters impacting dissolution rate
Tablet compression profiles and excipient systems controlling exposure
Controlled-release technologies if used

Launch risk for generics

If the marketed product is a specific polymorph with enforceable patents, generic may need a license or accept delay.
Even if the active ingredient is non-infringing by chemical structure, solid form enforcement can still create infringement theories.

How do method-of-use patents affect off-label vs on-label competition for DHODH inhibitors?

Method-of-use patents can:

Restrict generic labeling to “skinny label” approaches.
Create infringement risk if generic is marketed with instructions that fall within the patented method.

Infringement practicalities

If method claims align with standard-of-care practice, “skinny label” can be hard to maintain commercially.
If claims are patient-restricted or require specific biomarkers, generics can potentially carve out the patented population.

Enforcement leverage

Brand leverage increases when:

Method-of-use claims are broad enough to cover typical dosing and patient monitoring.
Patents were drafted around pivotal trial protocols that match real-world practice.

Which companies are likely competing in DHODH inhibitors and how do their patent estates differ?

Class-level competition is often split across:

Originator companies developing the first-in-class or best-in-class candidates
Follow-on companies developing close analogs with potentially distinct chemical space
Generic and biosimilar companies focusing on timing and challenge strategies

How to compare patent estates when facts are incomplete

Use three measurable estate metrics:

Earliest priority vs planned launch window
Earlier priority constrains generics sooner.
Late-cycle patent density (solid-state/formulation/method)
Higher density means more barriers after core compound expiry.
Claim breadth indicators
Broader Markush coverage and multiple jurisdiction filings signal stronger enforcement.

What patent litigation affects DHODH inhibitors and how do outcomes translate into market entry?

Litigation outcomes typically drive:

Automatic stays via settlement
At-risk launch periods
Design-around reformulations
Licensing deals for specific patents (often solid forms or method claims)

For an accurate litigation map, one must identify the exact DHODH inhibitor drug candidates and then query docketed cases by reference drug and patents. Without product-level identification, a factual litigation summary cannot be produced.

How does the regulatory pathway (NDA vs 505(b)(2) vs ANDA) change DHODH inhibitor IP strategy?

505(b)(2) route

Often used for reformulation or known drugs with bridging data.
Still subject to listed patents and potential exclusivity blocking depending on Orange Book status.

ANDA route

Requires patent certifications against listed Orange Book patents.
Para IV and settlement risk are the key entry determinants.

Labeling strategy

Even when composition patents expire, method-of-use patents and formulation patents can constrain label expansion.

Key patent estate indicators for DHODH inhibitors to monitor pre-launch

Use this checklist for each target DHODH inhibitor program:

Patent family count covering core compounds and the commercial solid form
Whether the approved formulation matches a patented polymorph/salt
Number of Orange Book listed patents and their staggered expiration dates
Method-of-use patents that track the label
Whether process patents exist that could raise manufacturing constraints
Jurisdiction coverage (US and major EP member states) for enforcement reach

Key Takeaways

DHODH inhibitor IP is typically anchored in composition-of-matter claims, with enforceability often extended by polymorph/salt and formulation patents.
Generic and follow-on risk is governed less by the early compound family alone and more by late-cycle solid-state and method-of-use patents that align with the marketed product.
Orange Book listings determine whether generic applicants must certify against multiple patents, shaping the likelihood of Paragraph IV litigation and settlement-driven launch delays.
Market adoption depends on clinical durability, safety, and payer-fit, which in turn affects how aggressively generics challenge and how quickly brands license or settle.

FAQs

How do solid-state (polymorph/salt) patents for DHODH inhibitors delay ANDA launches even after compound patents expire?
What Orange Book patent certifications are most likely to trigger Paragraph IV litigation for oral DHODH inhibitors?
Do method-of-use patents for DHODH inhibitors mainly restrict labeling (skinny label) or also prevent commercialization through infringement theories?
What design-around strategies are commonly used against Markush-based DHODH inhibitor composition patents?
How do regulatory exclusivity periods interact with patent term expirations for DHODH inhibitor products approved under different FDA pathways?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (U.S. FDA database). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
FDA. Patent Term Extensions and Relevant Policy. (U.S. FDA guidance/policy resources). https://www.fda.gov/drugs/patent-term-extensions